Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pacing method may improve heart failure treatment after ablation

NCT ID NCT05467163

Disease control Sponsor: University Medical Centre Ljubljana Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether a newer pacing method (conduction system pacing) is as good as or better than standard biventricular pacing in heart failure patients with atrial fibrillation who need a heart ablation. About 82 participants will be randomly assigned to one of the two pacing types. The main goal is to see how well the heart pumps blood after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pacemaker implantation (biventricular or conduction system pacing)
What this could lead to
If successful, this could show that conduction system pacing is a better option than standard biventricular pacing for managing heart failure after ablation.
What could go wrong
This is a mid-sized trial (82 participants) and results may not apply to all patients. The study is not yet recruiting, so outcomes are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 82 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Symptomatic permanent atrial fibrillation, refractory to drug therapy or failed catheter ablation 2. Left ventricular ejection fraction \<50% 3. Narrow intrinsic QRS ≤ 120 ms 4. NT-proBNP \> 600 ng/L 5. Patient has provided written informed consent 6. Age between 18 years and 85 years Exclusion Criteria: 1. Pre-existing permanent pacemaker, implantable cardioverter-defibrillator or cardiac resynchronization device. Patients who had devices implanted that had \<5% of paced beats (i.e., backup pacing) can be enrolled. 2. Life expectancy less than 12 months 3. Severe concomitant non-cardiac disease 4. Pregnancy 5. Recent (\<3 months) myocardial infarction, percutaneous or surgical myocardial revascularization 6. Significant heart valve disease (severe insufficiency or stenosis) 7. Contraindication for oral anticoagulation 8. Mechanical tricuspid valve replacement 9. Unwillingness to participate or lack of availability for follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation Heart failure Tachycardia-induced cardiomyopathy

Contacts and locations

Locations

  • Acibadem City Clinic Tokuda Hospital - Department of Invasive Electrophysiology

    Sofia, Bulgaria

  • Central-Hospital of Northern Pest - Military Hospital

    Budapest, 1134, Hungary

  • Clinical Hospital Center Rijeka

    Rijeka, Croatia

  • County Clinical emergency hospital of Brasov - Department of Interventional Cardiology

    Brasov, Romania

  • Hospital Oost-Limburg (Hartzentrum Genk)

    Genk, Belgium

  • University Hospital Centre Zagreb

    Zagreb, Croatia

  • University Hospital Graz - Divison of Cardiology

    Graz, Austria

  • University Hospital of Split

    Split, Croatia

  • University Medical Centre Ljubljana - Department of cardiology

    Ljubljana, 1000, Slovenia

  • University Medical Centre Ljubljana - Department of cardiovascular surgery

    Ljubljana, 1000, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.